3.2V or even 3.0V
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3- methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl] thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Research indicates that although semaglutide did not significantly improve hepatic fibrosis, it had positive effects on hepatic steatosis, weight control, and diabetes-related parameters, offering a new therapeutic direction for patients with NASH and compensated cirrhosis ( A study showed that the long-term use of GLP-1RAs could reduce the risk of major adverse liver events (MALE) in patients with type 2 diabetes
The starting dose is 2 mg per week
The study examines how -T3 affects biological processes such as cell viability, apoptosis, paraptosis, autophagy, and mitophagy (121)